OncLive TV

Eric Jonasch, MD, discusses the role of inhibiting hypoxia-inducible factor-2α in Von Hippel-Lindau disease–associated renal cell carcinoma.

Mikkael A. Sekeres, MD, discusses staging patients with myelodysplastic syndromes.

Anna C. Pavlick, DO, discusses the longer follow-up of the phase 2 EMPOWER-CSCC-1 study with cemiplimab in cutaneous squamous cell carcinoma.

Jennifer L. Atlas, MD, discusses the promise of cemiplimab in the treatment of patients with locally advanced cutaneous squamous cell carcinoma.

Christine Sam, MD, discusses strategies to mitigate the risk of the coronavirus disease 2019 in elderly patients with cancer.

Nabil F. Saba, MD, FACP, discusses ​emerging sequencing ​strategies in head and neck cancer. 

Sandra Cuellar, PharmD, BCOP, discusses challenges with ​data extrapolation for biosimilars. 

Denise Yardley, MD, discusses challenges with ​resistance mechanisms in hormone receptor–positive, HER2-negative breast cancer. 

Gina Z. D'Amato, MD, discusses the utility of next-generation sequencing in patients with stage I, II, or III sarcoma.

Erika P. Hamilton, MD, discusses updated data from the phase 2 HER2CLIMB trial examining tucatinib in patients with HER2-positive breast cancer and brain metastases.

Nilanjan Ghosh, MD, PhD, compares different BTK inhibitors in B-cell malignancies.

Joyce A. O'Shaughnessy, MD, discusses the utility of tucatinib in HER2-positive breast cancer with brain metastases.

David A. Reardon, MD, discusses the role of INO-5401 and INO-9012 in glioblastoma.

Mansoor Raza Mirza, MD,  discusses the safety ​profile of niraparib in combination with bevacizumab in platinum-sensitive recurrent ovarian cancer.

Paul A. Bunn, Jr MD, discusses potentially targeting HER3 in non–small cell lung cancer.

Erika P. Hamilton, MD, discusses the efficacy of fam-trastuzumab deruxtecan-nxki in HER2-low breast cancer.

John M. Pagel, MD, PhD, discusses challenges with autologous stem cell transplant in relapsed/refractory diffuse large B-cell lymphoma.

Grzegorz S. Nowakowski, MD, discusses the rationale for reevaluating the PCKß inhibitor enzastaurin in diffuse large B-cell lymphoma.

Sandy Wong, MD, discusses the potential role of venetoclax in relapsed/refractory light chain amyloidosis.

Jeffrey S. Weber, MD, PhD, discusses emerging therapies in melanoma.

Manfred Welslau, MD, discusses​ the potential benefits of ​using biosimilars in diffuse large B-cell lymphoma.

Ruben A. Mesa, MD, discusses accrual considerations in myeloproliferative neoplasms clinical trials. 

Anthony B. El-Khoueiry, MD, discusses the frontline treatment landscape of hepatocellular carcinoma.

Mansoor Raza Mirza, MD, discusses the clinical implications of the final survival analysis of the phase 3 NSGO-AVANOVA2/ENGOT-OV24 trial in recurrent, platinum-sensitive ovarian cancer.

Denise Yardley, MD, discusses the role of endocrine therapy in combination with CDK4/6 inhibitors in patients with hormone receptor–positive, HER2-negative breast cancer and visceral metastases.

Joyce F. Liu, MD, MPH, discusses the results of cediranib in combination with olaparib in a phase 3 trial in patients with recurrent platinum-sensitive ovarian cancer.

Toni K. Choueiri, MD, discusses the significance of the COVID-19 and Cancer Consortium during the coronavirus disease 2019 pandemic.

Nilanjan Ghosh, MD, PhD, discusses global trials examining zanubrutinib in mantle cell lymphoma and non-Hodgkin lymphoma.

Jennifer L. Atlas, MD, discusses the ​current cutaneous squamous cell carcinoma treatment paradigm.

Jennifer Woyach, MD, discusses the role of small molecule inhibitors in chronic lymphocytic leukemia.